Lupon Marta, Nolla Carme, Cardona Genis
Vision, Optometry and Health (VOS), Department of Optics and Optometry, Universitat Politècnica de Catalunya, Violinista Vellsolà 37, 08022 Terrassa, Spain.
Terrassa School of Optics and Optometry (FOOT), Universitat Politècnica de Catalunya, Violinista Vellsolà 37, 08022 Terrassa, Spain.
J Clin Med. 2024 Feb 19;13(4):1157. doi: 10.3390/jcm13041157.
Myopia control with new designs of spectacle lenses is a flourishing area of research. The present work reviews the effectiveness of new designs (DIMSs, defocus-incorporated multiple segments; CARE, cylindrical annular refractive element; HALs/SALs, highly/slightly aspherical lenslets; DOT, diffusion optics technology) aiming at slowing myopia progression. A search through the PubMed database was conducted for articles published between 1 January 2003 and 28 February 2023. Publications were included if they documented baseline central refraction (SER) and/or axial length (AL) data, and the change in these parameters, in myopic children wearing new designs of spectacle lenses (treatment group) compared to myopic children using single-vision lenses, SVLs (control group). The selection process revealed nine suitable articles. Comparing the mean and standard error values of the treatment and control groups, the highest differences in the change in the SER and AL were -0.80 (1.23) D [95% CI: -1.053 to -0.547; < 0.001] and 0.35 (0.05) mm [95% CI: 0.252 to 0.448; < 0.001], respectively; the effect of treatment provided by a HAL design, compared to SVLs, led to a deceleration of 54.8% in the SER and 50.7% in the AL. However, the heterogeneity of the results prevents reaching strong conclusions about the effectiveness of these new designs.
采用新型设计的眼镜片控制近视是一个蓬勃发展的研究领域。本研究综述了旨在减缓近视进展的新型设计(DIMS,离焦整合多区设计;CARE,柱面环形折射元件;HALs/SALs,高/微非球面小透镜;DOT,漫射光学技术)的有效性。通过PubMed数据库检索了2003年1月1日至2023年2月28日发表的文章。如果文章记录了佩戴新型设计眼镜片的近视儿童(治疗组)与使用单焦点镜片(SVLs)的近视儿童(对照组)的基线中央屈光不正(SER)和/或眼轴长度(AL)数据,以及这些参数的变化,则纳入该出版物。筛选过程共发现9篇合适的文章。比较治疗组和对照组的均值和标准误差值,SER和AL变化的最大差异分别为-0.80(1.23)D [95% CI:-1.053至-0.547;<0.001] 和0.35(0.05)mm [95% CI:0.252至0.448;<0.001];与SVLs相比,HAL设计提供的治疗效果使SER减慢了54.8%,AL减慢了50.7%。然而,结果的异质性使得无法就这些新设计的有效性得出强有力的结论。